Openbookopenbook
Equity
SLS
+0.0 · +0.00%
USD · NASDAQ

Sellas Life Sciences Group Inc(SLS) Stock Analysis | Healthcare

USD --+0.00%
Reward34Low
Risk72High
75%Data
Revenue down 83% YoY
Earnings Deterioration
Market Cap:2.67Bn
ⓘ
Reward Rating
34
Low
Reward Assessment
75% data coverage
Bottom 5% of stocksView factors
ⓘ
Risk Rating
72
High
Risk Assessment
2 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on SLS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for SLS, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $32.50.

What is Sellas Life Sciences Group Inc?

, a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.

SLS · Verdict

Limited reward · high risk

SLS's standout is balance sheet; cash flow and volatility weigh on the picture.

Based on 88% data coverage

SLS · Verdict

What’s working & what to watch

Strengths 1

  • Balance sheet100/100

    Current ratio 10.72

Watchouts 4

  • Cash flow5/100

    Weak vs peers

  • Volatility5/100

    Weak vs peers

  • Profitability10/100

    -40% return on equity

  • Growth31/100

    Earnings -13.4% CAGR

Model-based scoring. For information only — not financial advice.

What is Sellas Life Sciences Group Inc?

, a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.67B.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (34)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

ATAIMid Cap / 2.7B market cap
ATAI Life Sciences BV
Compare
TRVIMid Cap / 2.6B market cap
Trevi Therapeutics Inc
Compare
RAREMid Cap / 2.6B market cap
Ultragenyx
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap2.67B
P/E RatioN/A
Dividend YieldN/A
Beta2.494
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.